Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
– Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. –
DUBLIN–(BUSINESS WIRE)–DUBLIN – August 28, 2019 – Horizon Therapeutics plc (Nasdaq: HZNP) today named Andy Pasternak executive vice president, chief business officer, reporting directly to Timothy Walbert, chairman, president and chief executive officer, effective Nov. 1. Pasternak will join the Company’s executive committee and will lead business development, mergers and acquisitions, corporate strategy, commercial development and portfolio management.
“Bob has been an integral part in Horizon’s significant growth over the last five years, successfully leading our acquisition strategy as we have achieved our goal of becoming a profitable, rare disease biopharma company,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “Andy, in leading Bain’s Healthcare practice in the Americas, is an accomplished strategist who has helped global companies execute effectively, including Horizon for the last three years. His diverse industry experience, expertise in biotechnology, business development and leadership will be invaluable as we continue to build our pipeline and execute our long-term strategy.”
Pasternak will join Horizon from Bain & Company, Inc., a global management consulting firm, where he currently leads Bain’s Healthcare practice in the Americas. Andy joined Bain & Company as a partner in 2008. At Bain, Andy advises boards of directors, CEOs and leadership teams at biopharmaceutical and medical technology companies, as well as private investment funds. His experience spans growth strategy, M&A strategy and execution, organizational design, executive and board governance and performance improvement. Andy is also a member of Bain’s Mergers and Acquisition practice, where he serves as a leading expert on biopharmaceutical transactions, including acquisitions, business development, licensing deals and divestitures. In the biopharmaceutical space, Andy has worked across a wide range of specialty therapeutics areas, including rare diseases.
Prior to joining Bain, he was a founding partner in the Health & Life Sciences practice at Oliver Wyman, a global management consultancy.
Andy earned an MBA from the University of Chicago and a Bachelor of Arts in Economics from Northwestern University.
About Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts
U.S. Media Contacts:
Geoffrey Curtis
Executive Vice President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Matt Flesch
Executive Director, Product Communications
media@horizontherapeutics.com
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizontherapeutics.com
Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com
Ireland Media Contact:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie
